These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Inflamm Bowel Dis; 2004 Jul; 10(4):436-7. PubMed ID: 15475754 [Abstract] [Full Text] [Related]
7. [Indications and results of infliximab in Crohn's disease]. Karoui S, Boubaker J, Filali A. Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505 [Abstract] [Full Text] [Related]
8. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Seddik M, Melliez H, Seguy D, Viget N, Cortot A, Colombel JF. Inflamm Bowel Dis; 2005 Jun; 11(6):618-20. PubMed ID: 15905713 [No Abstract] [Full Text] [Related]
9. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S. Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301 [Abstract] [Full Text] [Related]
11. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Colorectal Dis; 2005 Mar 01; 7(2):164-8. PubMed ID: 15720356 [Abstract] [Full Text] [Related]
12. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724 [Abstract] [Full Text] [Related]
13. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Dis Colon Rectum; 2006 Dec 01; 49(12):1837-41. PubMed ID: 17041753 [Abstract] [Full Text] [Related]
14. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E. Aliment Pharmacol Ther; 2004 Oct 15; 20(8):851-7. PubMed ID: 15479356 [Abstract] [Full Text] [Related]
15. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G. Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684 [Abstract] [Full Text] [Related]
16. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Rutgeerts P, Van Assche G, Vermeire S. Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465 [Abstract] [Full Text] [Related]
19. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH]. Tilg H, Knoflach P, Petritsch W, Vogelsang H, Reinisch W, Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH. Z Gastroenterol; 2004 Oct 15; 42(10):1256-63. PubMed ID: 15508068 [No Abstract] [Full Text] [Related]
20. [Pneumocystis jiroveci pneumonia following infliximab therapy in patient with Crohn's disease]. Fluxá D, Segovia J, Florenzano M, Salinas J, Flores L, Simian D, Quera R. Rev Chilena Infectol; 2017 Oct 15; 34(5):518-519. PubMed ID: 29488599 [Abstract] [Full Text] [Related] Page: [Next] [New Search]